initi outperform pt
follow leader
pharma servic technolog disruptor superior execut
neutral share given skeptic
time core improv share gain addit
concern revenu ramp look steep manag
ultim admir job improv core momentum book
also prove forecast achiev strong
third quarter print de-risk enter believ
entiti notabl commerci momentum across major busi
segment look step-up core growth msd rang
includ front look continu proof point
trial product gain sustain market book growth
launch oce tech invest aid commerci growth
balanc sheet optim allow highli visibl tsr ldd
furthermor expect see modest omx build balanc
invest made integr asset acceler
growth yield improv top-lin perform coupl
disciplin approach b/ optim steadi capit alloc
forese ep growth sustain teen near-to-medium
term level highli visibl tsr quit uniqu view
especi given market cap excess result
continu upward expans rel multipl main risk
see enter would elev level pharma howev
given highli visibl natur revenu divers custom base
argu threat manag given dynam see posit
risk/reward thu initi share o/p
thing watch ebitda growth guid pace
book tax upsid
debat reboot cro strategi led share gain
legaci im sustain momentum msd rang
much capit alloc add ep growth
valuat price target base dcf
contempl wacc termin ebitda multipl
equat perpetu growth rate pt translat
forward ebitda vs average price-to-earnings basi
translat forward price-to-earnings vs average
downsid risk potenti larg scale biopharma
creat paus decis make ultim threaten path growth
improv shift fix price contract result mis-pric
cro busi result relationship loss make
time deterior cso organ given structur challeng
prove distract result execut issu across busi
iqv thesi around uniqu data prove untru
abil monet analysi fall short expect threat emerg
tech behemoth penetr healthcar challeng base im
franchis way disrupt price larg scale clinic trial failur
unanticip could disrupt growth trajectori suppress ttm
book nt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi outperform pt
follow leader
last page report import disclosur regard stock report
tabl content
compani overview cro power data scienc
debat reboot cro strategi led share gain
debat legaci im sustain momentum msd rang
debat much capit alloc add ep growth
point differenti vs st
iv valuat risk pharma vs visibl
 conclus initi o/p model evolut take hold
ia durham nc cro power data scienc
global cro unmatch scale tech solut
uniqu asset mix forg merger im
lead global provid inform innov
technolog solut cro servic focus use
data scienc help healthcar client find outcom
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk notabl up-tick larg scale biopharma
yield purchas delay limit core growth outlook
outsiz exposur develop market
tech-ori management w/ focu disrupt cro space
cegedim yr
debat reboot cro strategi led share gain
merger creat cro focus big data
seen earli success improv clinic oper
improv solut clinic trial
enhanc qs clinic trial biz use big data improv
clinic trial recruit product analysi
nextgen lead better clinic trial manag
idea smarter cro intrigu given
differ busi cautiou claim benefit
new busi
real-world data fuel next leg growth
develop nextgen cro oce offer base im
tech improv clinic commerci busi
day reduct site select day
day faster site start-up day
faster patient enrol
patients/site/month patients/site/month
use pipelin vs
acceler growth real-world insight studi
ttm book momentum build enter
benefit commercial/real-world insight rwi includ
work w/ top pharma rwi studi
take advantag pharma move
cloud-bas rwi
reduct time recruit real-world
month reduct regulatori respons time
bp improv diagnosi rate use
believ uniqu offer ultim lead share gain msd growth mt
compani file evercor isi
debat legaci im sustain momentum msd rang
post-merg reorgan led nois around legaci im busi abil maintain msd growth
reorgan post-merg better align busi
w/ aim creat real-world evidence-bas allianc
qs legaci busi under-perform vs im legaci
legaci im made differ busi
built around information/data offer data
wareh outsourc grow dd low-
data sourc robust offer vs
legaci im msd growth partial off-set qs busi
howev invest like drive growth across biz
acceler invest mcm re-
differenti offer base ai work
commerci oper
platform secondari advanc analyt
aim leverag tool win share
legaci im maintain msd invest acceler share gain
debat much capit alloc add ep growth
profil allow management keep co highli lever
tuck-in remain prioriti add growth
lead strong return compound mt
healthcar stock ex-biotech
cap space w/ attract profil
model summari point differenti vs street
swing factor book momentum cadenc omx vs invest bia capit alloc
point differenti
backlog convers
invest
ep in-lin w/ st
support
financi model increasingli uniqu cap size high level visibl
million except per share data fy end decemb organ organ engag organ organ gp less total op less ep share inc net inc price-to-earnings prem disc januari
valuat inflect higher post pre-merg feel period
share appear reason absolut rel basi given superior compound low risk profil
risk point favor risk reward profil superior execut capit alloc vs pharma
potenti larg scale biopharma creat paus decis make ultim threaten path growth improv
shift fix price contract result mispric cro busi result relationship loss make time
deterior cso organ given structur challeng prove distract result execut issu across busi
iqv thesi around uniqu data prove untru abil monet analysi fall short expect
threat emerg tech behemoth penetr healthcar challeng base im franchis way disrupt price
larg scale clinic trial failur unanticip could disrupt growth trajectori suppress ttm book nt
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
pharma servic technolog disruptor w/ super execut capit alloc yield teen compound
neutral share given skeptic time core
improv share gain addit concern revenu ramp look steep
manag ultim admir job improv core momentum book also
prove forecast achiev strong third quarter print de-risk
enter believ entiti notabl commerci momentum across major
busi segment look step-up core growth msd rang includ
 front look continu proof point trial product gain sustain market
book growth launch oce tech invest aid commerci growth
furthermor expect see modest omx build balanc invest
made integr asset acceler growth yield improv top-lin perform
coupl disciplin approach balanc sheet optim steadi capit
alloc forese ep growth sustain teen near-to-medium term
level highli visibl tsr quit uniqu view especi given market cap
excess result continu upward expans rel multipl
main risk see enter would elev level pharma howev given
highli visibl natur revenu divers custom base argu threat manag
given dynam see risk reward favor thu initi share o/p rate
thing watch ebitda growth guid pace book tax upsid
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog valuat methodolog base mix discount cash flow analysi rel valuat
risk disrupt revenu growth inabl replac unforeseen cancel new busi moder
biotech demand due capit market volatil dri invest paus rfp activ follow larg round
pharma industri consolid
laboratori corp america hold
articl articl
time dissemin januari et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
